Plasma proteomics reveals an improved cardio-metabolic profile in patients with type 2 diabetes post-liraglutide treatment

Background Diabetes mellitus is a chronic multisystem disease with a high global prevalence, including in Saudi Arabia. The Glucagon-like Peptide (GLP-1) receptor agonist liraglutide is known to lower glucose levels, reduce weight and improve cardiovascular outcome. However, mechanisms underlying th...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Diabetes & vascular disease research 2022-05, Vol.19 (3), p.14791641221094322-14791641221094322
Hauptverfasser:	Ekhzaimy, Aishah A, Masood, Afshan, Benabdelkamel, Hicham, Elhassan, Tasnem, Musambil, Mohthash, Alfadda, Assim A
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute-Phase Reaction - chemically induced Adult Blood Glucose - metabolism Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - drug therapy Glucagon-Like Peptide-1 Receptor - agonists Glycated Hemoglobin A - metabolism Humans Hypoglycemic Agents - adverse effects Liraglutide - adverse effects Metabolome Middle Aged Original Proteomics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!